Primary Outcomes:

Primary Outcome 1 - Measure: Number of subjects with adverse events (AE), including serious adverse events (SAEs).

Primary Outcome 1 - Time Frame: 3.5 years

Primary Outcome 2 - Measure: Determining dose limiting toxicities (DLT) and optimally tolerated dose range

Primary Outcome 2 - Time Frame: 3.5 years

Primary Outcome 3 - Measure: Evaluation of persistence of genetically modified T cells.

Primary Outcome 3 - Time Frame: 3.5 years

Primary Outcome 4 - Measure: Measurement of RCL in genetically modified T cells.

Primary Outcome 4 - Time Frame: 3.5 years

Condition:

• Urinary Bladder Cancer
• Melanoma
• Head and Neck Cancer
• Ovarian Cancer
• Non-Small Cell Lung Cancer
• Esophageal Cancer
• Gastric Cancer
• Synovial Sarcoma
• Myxoid Round Cell Liposarcoma
• Gastroesophageal Junction

Eligibility

Criteria:
Inclusion Criteria:

1. Subject is ≥18 years of age at the time of signing the study informed consent.

2. Subject has histologically confirmed diagnosis of any one of the indicated tumor types

3. Subject is HLA-A*02 positive. (This determination will be made under screening
protocol ADP-0000-001).

4. Subject's tumor shows expression of the MAGE-A4 RNA or protein. (This determination
will be made under screening protocol ADP-0000-001).

5. Adequate organ function as indicated in the study protocol

6. Subject has measurable disease according to RECIST v1.1 criteria prior to
lymphodepletion

7. Subject meets disease-specific requirements per protocol

7. Subject has anticipated life expectancy > 6 months prior to leukapheresis and >3 months
prior to lymphodepletion.

Exclusion Criteria:

1. Subject does not express appropriate HLA-A genotype

2. Subject is receiving excluded therapy/treatment per protocol

3. Subject has symptomatic CNS metastases.

4. Subject has any other active malignancy besides the tumor under study within 3 years
prior to Screening. Subject has uncontrolled intercurrent illness.

5. Subject has active infection with HIV, HBV, HCV or HTLV

6. Subject is pregnant or breastfeeding.

Additional Exclusion Criteria for the Radiation Substudy:

- Subject does not meet eligibility criteria for the main study (ADP-0044-001).

- Subject does not have at least one target lesion amenable to radiation.

- Certain radiation therapy within 6 months of clinical trial are an exclusion.

- Metastatic disease impinging on the spinal cord or threatening spinal cord
compression.
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Healthy Volunteers: No